Revisiting RECIST: the case of treatment beyond progression
A partir de données d'essais cliniques portant sur 2 624 patients atteints d'un mélanome de stade métastatique ou non résécable, cette étude analyse l'intérêt de continuer une immunothérapie par anticorps anti-PD-1 malgré la progression de la maladie telle que définie par les critères d'évaluation RECIST
The use of the standardised Response Evaluation Criteria in Solid Tumors (RECIST) to determine response to novel therapy has been a notable improvement in increasing reproducibility and confidence in the results of clinical trials.1,2 The first RECIST guidelines were published in 2000 and were biased towards identifying progression in ambiguous situations, with a view to preventing unnecessary treatment. RECIST is not based on any particular mechanistic understanding of response to therapy but rather aims to improve reproducibility among observers and reduce measurement error.
The Lancet Oncology , commentaire, 2017